CAESAREA, Israel, July 12, 2018 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ: DRIO), a leading global digital health company with mobile
health and big data solutions, announced today that
Research2Guidance, an analyst and strategic consulting company for
the digital health industry, published an interview of DarioHealth
CEO, Erez Raphael titled "Using
real-time data to feed predictive care models for diabetes
management." The interview covers topics including DarioHealth's
position and strategy in the digital health market, as well as
industry trends and a look at how users integrate digital health
technologies into their daily lives to create measurable health
benefits. To read the article in full, please visit:
https://research2guidance.com/using-real-time-data-to-feed-predictive-care-models-for-diabetes-management-interview-with-erez-raphael-ceo-at-dariohealth/
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital
health company serving its users with dynamic mobile health
solutions. In today's day and age, knowledge of health and
treatment is being democratized, and we believe people deserve to
know everything about their own health and have the best tools to
manage their condition. DarioHealth employs a revolutionary
approach whereby harnessing big data, we have developed a novel
method for chronic disease data management, empowering people to
analyze and personalize self-diabetes management in a totally new
way without having the disease slow them down. DarioHealth has a
commercial office in New York with
an R&D center in Caesarea,
Israel. For more information, visit
http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, we are using
forward-looking statements in the Research2Guidance interview, when
we discuss the benefits of our products to users, how our
capabilities help us empower diabetes patients and make a
significant difference in their lives, when we discuss that more
engaged users will lead to improvements in clinical outcomes, when
we discuss that we are looking into successfully expanding our
international market presence and having the same pricing model
helps us reach our revenue and profitability goals, when we discuss
acceleration of our penetration, when we discuss penetration rates
of digital health solutions, or that when digital health diabetes
solutions reach market penetration of 5%-10%, DarioHealth will be
one of the leading players digitizing diabetes
management, when we discuss expanding our business in the future to
serve and help improve the lives of patients with other chronic
conditions, or when we discuss our plan to accelerate user growth
and to be a dominant player in the market, and that this should
result in significantly higher revenue for the company.
Readers are cautioned that certain important factors may affect
the Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for
Dario™) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter,
VP Marketing,
joao@mydario.com
1-914-775-5548
DarioHealth Investor Relations Contact:
Westwicke Partners
Dario@Westwicke.com
1-443-213-0500
View original
content:http://www.prnewswire.com/news-releases/dariohealth-ceo-erez-raphaels-interview-published-in-research-2-guidance-300680056.html
SOURCE DarioHealth Corp.